Adagene Forges Ahead with Promising Cancer Drug and Strategic Alliances

SAN DIEGO, CA – January 23, 2026 – Adagene Inc. today outlined a confident path forward, bolstered by encouraging clinical results for its lead cancer immunotherapy, a robust financial position, and a growing web of strategic partnerships with pharmaceutical giants like Sanofi and Roche. The biotech firm (Nasdaq: ADAG) announced it holds $74.5 million in unaudited cash, providing a runway into late 2027, as it prepares for a series of critical data readouts in 2026 for its flagship drug, muzastotug.

The update positions Adagene as a significant player in the quest to treat microsatellite stable metastatic colorectal cancer (MSS CRC), a notoriously difficult-to-treat disease that accounts for over 80% of all colorectal cancers and has historically shown poor response to immunotherapy.

A Potential Breakthrough in a Challenging Cancer

At the heart of Adagene’s progress is muzastotug, a next-generation anti-CTLA-4 antibody designed with the company's proprietary SAFEbody precision masking technology. The drug, being tested in combination with Merck’s blockbuster anti-PD-1 therapy KEYTRUDA® (pembrolizumab), has shown promising results in a patient population with a high unmet need.

Updated data from the Phase 1b/2 study, presented at the 2025 American Society of Clinical Oncology (ASCO) meeting, demonstrated notable efficacy in third-line or later MSS CRC patients without active liver metastases. In the 20 mg/kg dose cohort, the combination achieved a confirmed objective response rate (ORR) of 29% and a disease control rate (DCR) of 81%. For context, single-agent immunotherapies have struggled to make a dent in MSS CRC, and even some combination therapies have yielded lower response rates. For instance, a recent Phase 2 study of pembrolizumab combined with capecitabine and bevacizumab showed an ORR of just 5%.

Perhaps more importantly, muzastotug demonstrated a highly favorable safety profile. The SAFEbody design allowed for dosing at levels 10 to 20 times higher than first-generation CTLA-4 inhibitors like ipilimumab, which are often limited by severe immune-related side effects. Adagene reported a low rate of high-grade treatment-related adverse events (TRAEs) and a treatment discontinuation rate of only 4%, a stark contrast to other CTLA-4 combinations that have reported higher toxicity, such as the 21% rate of severe colitis seen with the investigational drug botensilimab in a similar setting.

This compelling blend of safety and efficacy earned the muzastotug-pembrolizumab combination a Fast Track designation from the U.S. Food and Drug Administration (FDA). The company also confirmed it has reached alignment with the FDA on the design for its pivotal Phase 2 and Phase 3 trials, a crucial step that de-risks the regulatory path forward. A randomized Phase 2 dose-optimization study is already underway, with the first patient dosed in October 2025.

The SAFEbody Advantage: Precision Targeting to Unlock Potency

Adagene’s progress is underpinned by its innovative SAFEbody platform, which aims to solve a fundamental challenge in cancer therapy: maximizing a drug's power against tumors while minimizing collateral damage to healthy tissue. The technology works by attaching a "mask" to the antibody's active binding site. This mask is engineered to be cleaved off only in the unique conditions of the tumor microenvironment, which is often characterized by high concentrations of specific enzymes.

For muzastotug, this means the potent CTLA-4-blocking antibody is "unleashed" primarily within the tumor itself. There, it targets and depletes regulatory T cells (Tregs), a type of immune cell that suppresses the body's anti-cancer response. By removing these "brakes" on the immune system locally, muzastotug allows cancer-fighting T cells, further activated by pembrolizumab, to attack the tumor more effectively.

This precision-guided approach avoids the widespread systemic immune activation that causes the severe side effects associated with older CTLA-4 drugs. The ability to safely deliver higher, more effective doses could be the key to turning "cold," immunologically unresponsive tumors like MSS CRC into "hot" tumors that are susceptible to immunotherapy. The platform's versatility is further highlighted by Adagene's collaborations to develop masked antibody-drug conjugates (ADCs) with Exelixis and masked T-cell engagers with Third Arc Bio, demonstrating its broad applicability across the next generation of antibody-based medicines.

Strategic Alliances and Financial Runway Validate Growth Strategy

Beyond the clinic, Adagene has executed a savvy business strategy, securing external validation and non-dilutive funding through a series of high-profile collaborations. The most significant is a multifaceted deal with French pharmaceutical giant Sanofi. Sanofi made a strategic investment of up to $25 million to directly support muzastotug’s ongoing randomized Phase 2 study.

In a separate agreement, Adagene will supply muzastotug to Sanofi for a Phase 1/2 trial to evaluate it in combination with other anticancer therapies in over 100 patients, broadening the drug's potential applications. Sanofi’s decision to also exercise an option for a third discovery program using the SAFEbody platform signals deep confidence in Adagene's underlying technology.

This partnership is one of several that bolster Adagene's pipeline and balance sheet. The company is also working with Roche to test muzastotug in a triplet combination for first-line liver cancer and is advancing multiple programs with partners like Exelixis and ConjugateBio. These deals not only provide crucial capital but also validate the SAFEbody platform in the eyes of major industry players, a critical metric for emerging biotech firms.

This strategic success, combined with disciplined spending, has resulted in an unaudited cash position of $74.5 million as of year-end 2025. The company projects this provides a sufficient financial runway into late 2027, giving it the stability to pursue its ambitious clinical and business development goals without immediate financing pressures.

A Packed 2026: Key Catalysts on the Horizon

With a clear regulatory path, strong partnerships, and a solid financial foundation, Adagene is poised for a catalyst-rich 2026. The company has laid out an aggressive timeline for data releases that will be closely watched by investors and the oncology community.

A key data update from the ongoing Phase 1b/2 study of muzastotug plus pembrolizumab is expected in the first quarter of 2026, which will provide more mature results from over 60 patients across different dose cohorts. The company also aims to complete enrollment for its randomized Phase 2 dose-optimization study, a critical step toward a pivotal Phase 3 trial.

Furthermore, initial clinical data is expected from several other trials, including an investigator-initiated study of muzastotug in the neoadjuvant (pre-surgery) setting for colorectal cancer and a new cohort evaluating a triplet combination with the standard-of-care drug fruquintinib. Results from the collaboration with Roche in liver cancer are also anticipated, which could significantly expand muzastotug's market potential.

"Our strategy for muzastotug is grounded in Nobel Prize-recognized advances in regulatory T cell biology," said Peter Luo, Ph.D., CEO and President of R&D at Adagene. "In 2026, we hope new data will demonstrate muzastotug’s broad applicability, positioning it as a potentially transformative next-generation backbone therapy that can be used in combination across multiple indications."

This steady stream of anticipated news flow throughout the year will provide multiple opportunities for Adagene to demonstrate the value of its lead asset and its underlying technology platform, potentially reshaping treatment paradigms for some of today's most challenging cancers.